title: Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma.
abstract: The aim of this study was to investigate an association between the development of cholangiocarcinoma (CCA) and the ABO variant rs505922 (known to increase pancreatic cancer risk) in a large cohort of European individuals with CCA. In total, 180 individuals with CCA and 350 CCA-free controls were included. The ABO variant rs505922 was genotyped using a polymerase chain reaction-based assay. Association between this single nucleotide polymorphism (SNP) and CCA was tested in contingency tables. Neither allele distributions nor association tests and regression analysis provided evidence for an increased risk of CCA among carriers of the ABO variant (all P > 0.05). Nevertheless, we documented a deviation from Hardy-Weinberg equilibrium in the entire CCA cohort (P = 0.028) and for patients with intrahepatic (P = 0.037) but not extrahepatic tumor localization (P > 0.05). The association tests did not provide evidence for a prominent role of the investigated SNP in the genetic risk of CCA. However, Hardy-Weinberg disequilibrium in the entire cohort and the intrahepatic CCA subgroup warrants future studies investigating a potential CCA risk modulation by individual blood groups.
authors.forename: Marcin
authors.initials: M
authors.lastname: Krawczyk
authors.forename: Florentina
authors.initials: F
authors.lastname: Mihalache
authors.forename: Aksana
authors.initials: A
authors.lastname: Höblinger
authors.forename: Monica
authors.initials: M
authors.lastname: Acalovschi
authors.forename: Frank
authors.initials: F
authors.lastname: Lammert
authors.forename: Vincent
authors.initials: V
authors.lastname: Zimmer
mesh_terms: D000017:ABO Blood-Group System; D006801:Humans; D010190:Pancreatic Neoplasms / Q000097:blood*
chemical_list: D000017:ABO Blood-Group System